| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
77,921,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
4,773,204 |
Avg
Vol: |
2,175,956 |
| 52
Week Range: |
$81.49 - $81.49 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
S&P 400 MIDCAP |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Baldino Frank Jr |
Chairman & CEO |
• • – |
2004-12-17 |
4 |
D |
$48.99 |
$319,219 |
D/D |
(6,516) |
351,818 |
|
- |
|
| Buchi J Kevin |
Sr. Vice President and CFO |
• – – |
2004-12-17 |
4 |
D |
$48.99 |
$61,874 |
D/D |
(1,263) |
71,790 |
|
- |
|
| Grebow Peter E |
Sr VP,Worldwide Technical Ops. |
• – – |
2004-12-17 |
4 |
D |
$48.99 |
$56,387 |
D/D |
(1,151) |
55,291 |
|
- |
|
| Savini Carl A |
Sr. VP, Administration |
• – – |
2004-12-17 |
4 |
D |
$48.99 |
$56,387 |
D/D |
(1,151) |
33,586 |
|
- |
|
| Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-17 |
4 |
D |
$48.99 |
$61,874 |
D/D |
(1,263) |
29,250 |
|
- |
|
| Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-17 |
4 |
S |
$48.18 |
$199,940 |
D/D |
(4,149) |
30,513 |
|
- |
|
| Vaught Jeffry L |
Sr. Vice Pres., and Pres., R&D |
• – – |
2004-12-17 |
4 |
D |
$48.99 |
$56,387 |
D/D |
(1,151) |
36,987 |
|
- |
|
| Blake Paul |
Sr VP, Clin Research & Reg Aff |
• – – |
2004-12-17 |
4 |
D |
$48.99 |
$75,004 |
D/D |
(1,531) |
35,000 |
|
- |
|
| Blake Paul |
Sr VP, Clin Research & Reg Aff |
• – – |
2004-12-17 |
4 |
S |
$49.28 |
$170,952 |
D/D |
(3,469) |
36,531 |
|
- |
|
| Roche Robert P Jr |
Sr. V.P., Pharmaceutical Ops. |
• – – |
2004-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
45,840 |
|
- |
|
| Baldino Frank Jr |
Chairman & CEO |
• • – |
2004-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
358,334 |
|
- |
|
| Buchi J Kevin |
Sr. Vice President and CFO |
• – – |
2004-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
73,053 |
|
- |
|
| Grebow Peter E |
Sr VP,Worldwide Technical Ops. |
• – – |
2004-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
56,442 |
|
- |
|
| Savini Carl A |
Sr. VP, Administration |
• – – |
2004-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
34,737 |
|
- |
|
| Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
34,662 |
|
- |
|
| Vaught Jeffry L |
Sr. Vice Pres., and Pres., R&D |
• – – |
2004-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
38,138 |
|
- |
|
| Blake Paul |
Sr VP, Clin Research & Reg Aff |
• – – |
2004-12-16 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
40,000 |
|
- |
|
| Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-15 |
4 |
S |
$48.32 |
$969,740 |
D/D |
(20,000) |
16,662 |
|
- |
|
| Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-15 |
4 |
OE |
$24.25 |
$485,000 |
D/D |
20,000 |
36,662 |
|
- |
|
| Osborn John E |
Sr. VP, General Counsel & Sec. |
• – – |
2004-12-14 |
4 |
S |
$48.00 |
$163,200 |
D/D |
(3,400) |
16,662 |
|
- |
|
| Roche Robert P Jr |
Sr. V.P., Pharmaceutical Ops. |
• – – |
2004-12-13 |
4 |
D |
$48.06 |
$36,670 |
D/D |
(763) |
27,840 |
|
- |
|
| Baldino Frank Jr |
Chairman & CEO |
• • – |
2004-12-13 |
4 |
D |
$48.06 |
$183,349 |
D/D |
(3,815) |
268,334 |
|
- |
|
| Buchi J Kevin |
Sr. Vice President and CFO |
• – – |
2004-12-13 |
4 |
D |
$48.06 |
$40,274 |
D/D |
(838) |
55,053 |
|
- |
|
| Grebow Peter E |
Sr VP,Worldwide Technical Ops. |
• – – |
2004-12-13 |
4 |
D |
$48.06 |
$36,670 |
D/D |
(763) |
38,402 |
|
- |
|
| Savini Carl A |
Sr. VP, Administration |
• – – |
2004-12-13 |
4 |
D |
$48.06 |
$36,670 |
D/D |
(763) |
16,737 |
|
- |
|
491 Records found
|
|
Page 17 of 20 |
|
|
